Effect of zoledronic acid on bone metabolism in prostate cancer (T3NXMO) patients on the androgen deprivation

被引：0
|
作者：
不详
机构：
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2006年 / 5卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：205 / 205
页数：1
相关论文
共 50 条
  • [41] Zoledronic acid effective as treatment for bone complications in prostate cancer patients
    不详
    ONCOLOGY-NEW YORK, 2002, 16 (09): : 1202 - 1202
  • [42] Zoledronic acid reduces bone resorption in patients with hormone prostate cancer
    Drudge-Coates, L.
    Rajbabu, K.
    Walsh, K.
    Thompson, P. M.
    Muir, G.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 98 - 98
  • [43] Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer
    Greenspan, SL
    Coates, P
    Sereika, SM
    Nelson, JB
    Trump, DL
    Resnick, NM
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (12): : 6410 - 6417
  • [44] EFFECTS OF ANDROGEN DEPRIVATION THERAPY ON BONE QUALITY (TBS) IN PATIENTS WITH PROSTATE CANCER
    Garcia-Cirera, S.
    Casado, E.
    Munoz, J.
    Del Rio, L.
    Arevalo, M.
    Rusinol, M.
    Navarro, N.
    Parejo, V.
    Gratacos, J.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S459 - S459
  • [45] EFFECTS OF ANDROGEN DEPRIVATION THERAPY ON BONE QUALITY (TBS) IN PATIENTS WITH PROSTATE CANCER
    Garcia-Cirera, S.
    Casado, E.
    Munoz, J.
    Del Rio, L.
    Arevalo, M.
    Rusinol, M.
    Navarro, N.
    Parejo, V.
    Gratacos-Masmitja, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1187 - 1188
  • [46] The use of zoledronic acid in patients with bone metastases from prostate carcinoma: Effect on analgesic response and bone metabolism biomarkers
    Fulfaro, F
    Leto, G
    Badalamenti, G
    Arcara, C
    Cicero, G
    Valerio, MR
    Di Fede, G
    Russo, A
    Vitale, A
    Rini, GB
    Casuccio, A
    Intrivici, C
    Gebbia, N
    JOURNAL OF CHEMOTHERAPY, 2005, 17 (05) : 555 - 559
  • [47] Randomized study on the effect of zoledronic acid treatment for prostate cancer with bone metastasis during initial combined androgen blockade
    Ueno, Satoru
    Mizokami, Atsushi
    Namiki, Mikio
    Fukagai, Takashi
    Fujimoto, Naohiro
    Ooka, Hitoshi
    Kondo, Yukihiro
    Arai, Gaku
    Ide, Hisamitsu
    Kataoka, Kazuyoshi
    Kawaguchi, Kohei
    Shimamura, Masayoshi
    Orito, Matsuo
    Ishida, Takeyuki
    Ikeda, Daisuke
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [48] Sustained suppression of bone turnover in androgen-deprived prostate cancer patients receiving infrequent infusions of zoledronic acid
    Ryan, CW
    Huo, D
    Stadler, WM
    McWhorter, LT
    Vogelzang, NJ
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 : P68 - P68
  • [49] Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-na⟨ve prostate cancer with bone metastasis
    Nozawa, Masahiro
    Inagaki, Takeshi
    Nagao, Kazuhiro
    Nishioka, Tsukasa
    Komura, Takahiro
    Esa, Atsunobu
    Kitagawa, Michio
    Imanishi, Masaaki
    Uekado, Yasunari
    Ogawa, Takatoshi
    Kajikawa, Hiroshi
    Uejima, Shigeya
    Matsuyama, Hideyasu
    Hara, Isao
    Uemura, Hirotsugu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (04) : 693 - 701
  • [50] Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis
    Masahiro Nozawa
    Takeshi Inagaki
    Kazuhiro Nagao
    Tsukasa Nishioka
    Takahiro Komura
    Atsunobu Esa
    Michio Kitagawa
    Masaaki Imanishi
    Yasunari Uekado
    Takatoshi Ogawa
    Hiroshi Kajikawa
    Shigeya Uejima
    Hideyasu Matsuyama
    Isao Hara
    Hirotsugu Uemura
    International Journal of Clinical Oncology, 2014, 19 : 693 - 701
12345